| Table of Contents, Volume 193, Number 4, December 2023 |
|
|
|
|
|
|
|
|
|
| Cover Image, Volume 193, Number 4, December 2023 |
|
|
|
|
|
|
|
|
|
| Down syndrome across the lifespan |
|
|
|
|
|
|
|
|
|
| Retrospective review of the code status of individuals with <scp>Down</scp> syndrome during the <scp>COVID‐19</scp> era |
|
|
|
|
|
|
|
|
|
| Listening to patients with suspected genetic diagnoses: A narrative perspective |
|
|
|
|
|
|
|
|
|
| Takotsubo cardiomyopathy secondary to electroconvulsive therapy in a young adult with Down syndrome regression disorder |
|
|
|
|
|
|
|
|
|
| Children with Down syndrome who experience developmental skill loss, characterization, and phenomenology: A case series |
|
|
|
|
|
|
|
|
|
| Health care satisfaction and medical literacy habits among caregivers of individuals with Down syndrome |
|
|
|
|
|
|
|
|
|
| Family adaptation in families of individuals with <scp>Down</scp> syndrome from 12 countries |
|
|
|
|
|
|
|
|
|
| Normal joint range of motion in children with Down syndrome |
|
|
|
|
|
|
|
|
|
| The Pediatric Integrated Care Survey (<scp>PICS</scp>) in a multidisciplinary clinic for Down syndrome |
|
|
|
|
|
|
|
|
|
| Quality of life measures in children with Down syndrome with disorders of gut–brain interaction |
|
|
|
|
|
|
|
|
|
| Co‐occurring conditions in Down syndrome: Findings from a clinical database |
|
|
|
|
|
|
|
|
|
| Pneumonia vaccine response in individuals with Down syndrome at three specialty clinics |
|
|
|
|
|
|
|
|
|
| Psychopharmacological treatments in Down syndrome and autism spectrum disorder: State of the research and practical considerations |
|
|
|
|
|
|
|
|
|
| Altered sleep architecture in children and adolescents with Down syndrome |
|
|
|
|
|
|
|
|
|
| Brief report: Physical activity assessment and counseling in adults with Down syndrome |
|
|
|
|
|
|
|
|
|
| Ophthalmologic and neuro‐ophthalmologic findings in children with Down syndrome |
|
|
|
|
|
|
|
|
|
| Table of Contents, Volume 193, Number 3, September 2023 |
|
|
|
|
|
|
|
|
|
| Publication schedule for 2023 |
|
|
|
|
|
|
|
|
|
| Cover Image, Volume 193, Number 3, September 2023 |
|
|
|
|
|
|
|
|
|
| Beyond chromosome analysis: Additional genetic testing practice in a Down syndrome clinic |
|
|
|
|
|
|
|
|
|
| Sustainability of personal social networks of people with Down syndrome |
|
|
|
|
|
|
|
|
|
| Healthy transition: Roadmap for young adults with Down syndrome to adulthood |
|
|
|
|
|
|
|
|
|
| Integration of <scp>EpiSign</scp>, facial phenotyping, and likelihood ratio interpretation of clinical abnormalities in the re‐classification of an <scp><i>ARID1B</i></scp> missense variant |
|
|
|
|
|
|
|
|
|
| Computational facial analysis for rare Mendelian disorders |
|
|
|
|
|
|
|
|
|
| Is artificial intelligence getting too much credit in medical genetics? |
|
|
|
|
|
|
|
|
|
| Artificial intelligence and the impact on medical genetics |
|
|
|
|
|
|
|
|
|
| Application of facial analysis Technology in Clinical Genetics: Considerations for diverse populations |
|
|
|
|
|
✓ |
✓ |
✓ |
populations of European descent; ancestrally diverse backgrounds; diverse population groups; diverse populations |
| Development of webcam‐collected and artificial‐intelligence‐derived social and cognitive performance measures for neurodevelopmental genetic syndromes |
|
|
|
|
|
|
|
|
|
| Applications of artificial intelligence in clinical laboratory genomics |
|
|
|
|
|
|
|
|
|
| Publication schedule for 2023 |
|
|
|
|
|
|
|
|
|
| Cover Image, Volume 193, Number 2, June 2023 |
|
|
|
|
|
|
|
|
|
| Table of Contents, Volume 193, Number 2, June 2023 |
|
|
|
|
|
|
|
|
|
| Unmasking the challenges of <scp>Kabuki</scp> syndrome in adulthood: A case series |
|
|
|
|
|
|
|
|
|
| Autosomal dominant genodermatoses in adults being heralded by superimposed skin lesions in children |
|
|
|
|
|
|
|
|
|
| Neurodevelopmental and other psychiatric disorders in 22q11.2 deletion syndrome from childhood to adult age: Prospective longitudinal study of 100 individuals |
|
|
|
|
|
|
|
|
|
| Spectrum of white matter abnormalities associated with <scp><i>FOXC1</i></scp>‐related disorders in two unrelated cases |
|
|
|
|
|
|
|
|
|
| Spondyloepimetaphyseal dysplasia with joint laxity type 2: Aggregating the literature and reporting on the life of a 66‐year‐old man |
|
|
|
|
|
|
|
|
|
| Rod‐cone dystrophy in an adult with <scp><i>GNB1</i></scp>‐related disorder: An expansion of the phenotype and natural history |
|
|
|
|
|
|
|
|
|
| Adult experiences in Beckwith–Wiedemann syndrome |
|
|
|
|
|
|
|
|
|
| Autism and mild epilepsy associated with a de novo missense pathogenic variant in the <scp>GTPase</scp> effector domain of <scp>DNM1</scp> |
|
|
|
|
|
|
|
|
|
| Mental health in adults living with arthrogryposis multiplex congenita |
|
|
|
|
|
|
|
|
|
| <i>DNAJC21</i>‐related thrombocytopenia in a young adult female |
|
|
|
|
|
|
|
|
|
| Caregivers' concerns and supports needed to care for adults with Down syndrome |
|
|
|
|
|
|
|
|
|
| Age‐related survey of clinical genetics literature and related resources |
|
|
|
|
|
|
|
|
|
| Cover Image, Volume 193, Number 1, March 2023 |
|
|
|
|
|
|
|
|
|
| Table of Contents, Volume 193, Number 1, March 2023 |
|
|
|
|
|
|
|
|
|
| Note from the editors |
|
|
|
|
|
|
|
|
|
| Publication schedule for 2023 |
|
|
|
|
|
|
|
|
|
| <i>COL1A1</i> and <i>COL1A2</i> variants in <scp>Ehlers‐Danlos</scp> syndrome phenotypes and <scp>COL1</scp>‐related overlap disorder |
|
|
|
|
|
|
|
|
|
| When is the best time to screen and evaluate for treatable genetic disorders?: A lifespan perspective |
|
|
|
|
|
|
|
|
|
| Gene‐targeted therapies: Overview and implications |
|
|
|
|
|
|
|
|
|
| A review of economic issues for <scp>gene‐targeted</scp> therapies: Value, affordability, and access |
|
|
|
|
|
|
|
|
|
| Privacy, bias and the clinical use of facial recognition technology: A survey of genetics professionals |
|
|
|
|
|
|
|
|
|
| Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies |
|
|
|
|
|
|
|
|
|
| Natural history of <i>MRAS</i>‐related Noonan syndrome: Evidence of mild adult‐onset left ventricular hypertrophy and neuropsychiatric features |
|
|
|
|
|
|
|
|
|
| Are we prepared to deliver gene‐targeted therapies for rare diseases? |
|
|
|
|
|
|
|
|
|
| Gene‐targeted therapies: Towards equitable development, diagnosis, and access |
|
|
|
|
|
|
|
|
|
| Data sharing to advance gene‐targeted therapies in rare diseases |
|
|
|
|
|
|
|
|
|